These findings parallel a recent observation in patients with T2D and NAFLD, in whom treatment with SGLT2-inhibitors was linked with improvement of liver steatosis and fibrosis markers and circulating pro-inflammatory and redox status [278]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.